Stephane Peluso - 02 Aug 2022 Form 4 Insider Report for INFINITY PHARMACEUTICALS, INC.

Reporting relationship: Chief Scientific Officer
Issuer ticker: N/A
Reported as of: 02 Aug 2022
Net transaction value: +$9,932
SEC form: 4
Accepted by SEC: 04 Aug 2022, 18:26:16 UTC
Prior SEC filing: 12 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Stephane Peluso

Key filing fact

Stephane Peluso filed Form 4 for INFINITY PHARMACEUTICALS, INC. on 04 Aug 2022.

Key facts

This page summarizes Stephane Peluso's Form 4 filing for INFINITY PHARMACEUTICALS, INC..
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Aug 2022, 18:26.

Change

Previous filing in this sequence was filed on 12 Jan 2022.
Current net transaction value: +$9,932.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INFI transaction

Common Stock

Options Exercise

Transaction value
Shares: +50,000
Change %: +2444%
Price
Shares after: 52,046
Date: 02 Aug 2022
Ownership: Direct
Footnotes: F1

INFI transaction

Common Stock

Sale

Transaction value: $9,932
Shares: +14,994
Change %: +68%
Price: $0.6624^*
Shares after: 37,052
Date: 02 Aug 2022
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INFI transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -50,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Restricted stock units ("RSUs") convert into Common Stock of the issuer on a one-for-one basis. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date.

Footnote F2

Represents the shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the RSUs listed in Table II. This sale does not represent a discretionary trade by the reporting person.

Footnote F3

On August 2, 2021, the reporting person was granted RSUs, of which all 50,000 vested as of August 2, 2022.